The Role of the 14–20 Domain of the Islet Amyloid Polypeptide in Amyloid Formation by Gilead, Sharon & Gazit, Ehud
Hindawi Publishing Corporation
Experimental Diabetes Research
Volume 2008, Article ID 256954, 8 pages
doi:10.1155/2008/256954
ResearchArticle
The Role of the 14–20 Domain of the Islet Amyloid
Polypeptide in Amyloid Formation
Sharon Gilead and Ehud Gazit
Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences,
Tel Aviv University, Tel Aviv 69978, Israel
Correspondence should be addressed to Ehud Gazit, ehudg@post.tau.ac.il
Received 7 September 2007; Revised 19 March 2008; Accepted 2 May 2008
Recommended by Per Westermark
The molecular mechanism of amyloid formation by the islet amyloid polypeptide (IAPP) has been intensively studied since its
identiﬁcation in the late 1980s. The IAPP(20–29) region is considered to be the central amyloidogenic module of the polypeptide.
This assumption is mainly based on the amyloidogenic properties of the region and on the large sequence diversity within this
region between the human and mouse IAPP, as the mouse IAPP does not form amyloids. A few years ago, another region within
IAPP was identiﬁed that seems to be at least as important as IAPP(20–29) in facilitation of molecular recognition that leads
to amyloid formation. Here, we reinforce our and others’ previous ﬁndings by analyzing supporting evidence from the recent
literature. Moreover, we provide new proofs to our hypothesis by comparing between the amyloidogenic properties of the two
regions derived from the IAPP of cats, which is also known to form amyloid ﬁbrils.
Copyright © 2008 S. Gilead and E. Gazit. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The islet amyloid polypeptide (IAPP) is a 37 amino acid
hormone, which is colocalized with insulin in the pancreatic
β-cells. The two polypeptides are cosecreted in response to
β-cell stimulation [1–4]. In 1986 and 1987, Westermark et al.
and Cooper et al. identiﬁed IAPP (also designated asAmylin)
as the major component of pancreatic amyloid deposits, a
characteristic pathological feature of type II diabetes [5, 6].
As other amyloid-related proteins and polypeptides, the
IAPPidentiﬁedinthesedepositsisthewild-typepolypeptide
in most type II diabetes cases. In its physiological role, IAPP
acts as a regulator of glucose homeostasis [7–9].
Theformationofamyloidﬁbrils,whichisthehallmarkof
a group of more than twenty diseases, among them some of
themostdevastatingdisordersofthe20thcentury,isahighly
speciﬁc self-assembly process [10–14]. The accumulation
of IAPP, as well as of amyloidogenic proteins found in
other amyloid-related diseases, into amyloid ﬁbrils proceeds
via a self-recognition mechanism. The process involves a
structuraltransitionfromtheproteinnativestructure,which
is considered to be random coil in the case of IAPP, into a
cross-β-pleated-sheet secondary structure conformation.
The exact conditions that stimulate the aggregation
of amyloidogenic proteins are yet to be fully understood.
However, comprehension of the molecular traits of the amy-
loidogenic process may be highly valuable in the attempts to
understand and prevent this world aﬀecting phenomenon.
The identiﬁcation of IAPP in the late 1980s paved the way
for vast investigation regarding the molecular mechanism of
IAPPself-assemblyprocess.Acentralissueaddressedwasthe
search for the molecular elements that make IAPP highly
prone to amyloid formation. One of the ﬁrst observations
regardingIAPPamyloidogenicitywasthespeciespeciﬁcityof
this process [15, 16]. Although more than 80% of the IAPP
sequence is conserved in mammalians, only a few species
suchashumans,primates,andcatsdevelopisletamyloidand
suﬀerfromtypeIIdiabetes,whilemice,rats,anddogsdonot
develop islet amyloid deposits.
The most noticeable sequence diversity is the one be-
tween human and mouse/rat IAPP. The sequence of rodent
IAPP (rIAPP) diﬀers from that of human IAPP (hIAPP)
in 6 out of 37 amino acids, 5 of them are located in a
deﬁned region between residues 20 and 29 [hIAPP(20–29)
is SNNFGAILSS and rIAPP(20–29) is SNNLGPVLPP] [15–
17]. Moreover, the rodent IAPP contains within this region 32 Experimental Diabetes Research
proline residues, which are absent in the human sequence.
The proline residue is known to strongly unfavor β-sheet
structures. Therefore, the hIAPP(20–29) has been suggested
to be responsible for the amyloidogenic propensities of full-
length hIAPP.
The decapeptide sequence of hIAPP(20–29) was shown
to be able to aggregate into amyloids, whereas the cor-
responding rIAPP(20–29) did not [15–17]. Furthermore,
shorter peptide fragments derived from this region, the
penta- and hexapeptides sequences hIAPP(23–27) (FGAIL)
and hIAPP(22–27) (NFGAIL), were found to be suﬃcient
for the formation of amyloid-like structures [18]. Hence,
the hIAPP(20–29) has been used as a model to study
intermolecular interactions and β-sheet formation and was
considered to be the only recognition region of IAPP.
In 2001, Fraser et al. identiﬁed a previously unrecognized
amyloidogenicdomainofIAPPlocatedwithinresidues8–20.
Synthetic peptides corresponding to this region assembled
into ﬁbrils with typical amyloid-like morphology [19].
Thereafter, we identiﬁed, using an unbiased peptide array
analysis, a domain comprising the same region that showed
even higher aﬃnity recognition to IAPP as compared to the
hIAPP(20–29) region [20]. IAPP was incubated with a SPOT
membrane containing consecutive overlapping sequences of
the full-length hIAPP. Indeed, IAPP was found to bind to the
20–29 region, however a substantially stronger interaction to
a region within residues 11–20 was found. Moreover, peptide
fragments within this region were shown to readily form
amyloid-like structures, some of which are as short as pen-
tapeptides, corresponding to hIAPP(14–18) and hIAPP(15–
19). Thus, we suggested that this new identiﬁed region plays
a central role in the recognition as well as the self-assembly
of IAPP amyloid formation process.
During the last few years, accumulating data has sup-
portedourpreviousassumption,bothdirectlyandindirectly.
However, the hIAPP(20–29) has still remained the major
studied amyloidogenic region. Here, we pinpoint these
supporting evidences from the recent literature in order to
emphasize the relevance of the new recognition and self-
assembling region. Furthermore, we provide new proofs
for our hypothesis by investigating and comparing the
amyloidogenic propensity of the two regions derived from
the amyloidogenic cat IAPP (cIAPP).
2. MATERIALS AND METHODS
2.1. Peptidesolutions
Peptides were purchased from Peptron, Inc. (Taejeon,
Korea). Lyophilized peptides were dissolved in dimethyl
sulfoxide (DMSO) at a concentration of 100mM. To avoid
any preaggregation, fresh stock solutions were prepared for
each experiment. Peptide stock solutions were diluted into
10mM Tris buﬀer, pH 7.2 to a ﬁnal concentration of 2 or
5mM and 2% or 5% DMSO, respectively.
2.2. CongoRedstainingandbirefringence
A1 0μL suspension of 5mM peptide solution aged for 1 day
was allowed to dry overnight on a glass microscope slide.
Stainingwasperformedbytheadditionofa10μLsuspension
of saturated Congo Red (CR) and NaCl in 80% ethanol
(v/v)solution.BirefringencewasdeterminedwithanSZX-12
stereoscope (Olympus, Hamburg, Germany) equipped with
cross polarizers.
2.3. Transmissionelectronmicroscopy
A1 0 μL sample of 2 or 5mM peptide solution aged for 1
to 3 days was placed on a 400-mesh copper grid covered by
carbon-stabilized formvar ﬁlm (SPI supplies, West Chester
PA). After 1 minute, excess ﬂuid was removed, and the
grid was then negatively stained with 2% uranyl acetate in
water for another 2 minutes. Samples were viewed in a JEOL
1200EX electron microscope operating at 80kV.
2.4. Fourier-transforminfraredspectroscopy
A3 0 μL sample of 2mM peptide solution aged for 2 days
wassuspendedonapolytetraﬂuoroethylene(PTFE)cardand
driedbyvacuum.PeptidedepositwasresuspendedwithD2O
and subsequently dried. The resuspension procedure was
repeated twice to ensure maximal hydrogen to deuterium
exchange. Infrared spectra were recorded using a Nicolet
Nexus 470 FT-IR spectrometer with a DTGS detector.
3. RESULTS AND DISCUSSION
3.1. Identiﬁcationofotheramyloidogenic
regionswithinIAPP
The hIAPP(20–29) region was considered to be the central
amyloidogenic domain within hIAPP. In 1999 and 2001, two
other amyloidogenic regions, hIAPP(30–37) and hIAPP(8–
20), were identiﬁed to be able to form amyloid-like ﬁbrils in
a q u e o u sm e d i u ma sw e l l[ 19, 21]. Sequence examination of
these regions reveals a single amino acid variation between
the rodent and human sequences at position 18, displaying
Arg or His, respectively. At the C-terminus part, rIAPP(30–
37) and hIAPP(30–37) are completely homologous. Thus, it
was suggested that in the rodent molecule, two potentially
amyloidogenic domains exist but are separated by the
proline rich domain, residues 20–29, which prevent β-sheet
formation [4].
Shortly after the publication of our results regarding the
identiﬁcation of very short amyloid-forming peptides within
the IAPP(14–19) region [20], another study has shown the
presence of short amyloidogenic peptides within the 8–20
region [22]. By scanning a series of overlapping peptides
from the 8–20 region, two peptide fragments, IAPP(12–
17) and IAPP(15–20), were found to form amyloid-like
structures. This study gave a strong independent support
to our ﬁndings. All together these ﬁndings provided clear




The contribution of speciﬁc residues from diﬀerent regions
to hIAPP ﬁbrillization was also investigated in the contextS. Gilead and E. Gazit 3
of full-length IAPP by performing single and multiple
amino acid substitutions and assessing their inﬂuence on
amyloid ﬁbril formation. The ability of rIAPP variants
of single-residue substitutions with amino acids from the
corresponding positions of hIAPP was studied [23]. A
single substitution of Arg to His at position 18 (R18H),
in the full-length rIAPP, was found suﬃcient to render its
competence for ﬁbril formation at a small yield. Similar
results were observed with the single substitutions L23F
and V26I. In addition, the combination of two or three of
these substitutions generally increased the ability to produce
ﬁbrils. These results show that the presence of the three
proline residues in the rIAPP(20–29) domain is insuﬃcient
to abolish the ability to form ﬁbrils. Moreover, the ability
of the R18H variant of rIAPP to self-associate into amyloid
ﬁbrils suggests that other domains of IAPP except the 20–29
are involved in the self-recognition process.
The role of the histidine at position 18 in amyloid forma-
tion was further examined by assessing hIAPP ﬁbrillization
at various pH ranges [24]. The ionization state of His-18
was found to substantially aﬀect the rate of assembly as
well as the morphology of the amyloid ﬁbrils formed by
hIAPP. The aggregation process was faster at high pH (8.8),
when the histidine is deprotonated, than at low pH (4.0).
This fact may be physiologically relevant as mature hIAPP
is stored in the β-cell granules at a pH of 5.5 and released
into the extracellular matrix where the pH is of 7.4. Thus, the
low pH in the pancreatic granules may protect hIAPP from
aggregation.
Abedini and Raleigh, who performed the above-
described study, further questioned the exclusive importance
of the 20–29 region by designing a variant of the amy-
loidogenic hIAPP(8–37), containing three proline residues
outside this region, at positions 17, 19, and 30 [25]. The
3×P variant had dramatically greater solubility and reduced
tendency to form β-sheet structures compared to the wild-
type polypeptide, as assayed by a variety of amyloid-
detecting techniques. The authors concluded that models of
IAPP ﬁbrillization must take into account contributions of
other regions within IAPP.
3.3. InhibitionofhIAPPamyloidformation
Based on our identiﬁcation of the hIAPP(13–18) recognition
site, we designed peptide inhibitors against IAPP ﬁbrilliza-
tion, which were targeted to this region. Using the previously
exempliﬁed method of incorporating β-breaker elements
into amyloidogenic core peptides [26], we introduced a new
inhibition strategy using the α-aminoisobutyric acid (Aib),
a β-breaker element with extreme structural constrains [27].
Peptide fragments corresponding to the recognition domain
were modiﬁed with Aib. The modiﬁed peptides completely
lost their amyloidogenic potential. Furthermore, the Aib-
modiﬁed peptide showed a powerful inhibitory eﬀect on the
formation of amyloid ﬁbrils by the full-length hIAPP.
Evidently, the 20–29 region was also used as a template
for inhibitor design and served as a target for inhibition.
Kapurniotu et al. designed a nonamyloidogenic and bioac-
tivemimicofhIAPP,whichcontainsadoubleN-methylation
of full-length hIAPP at positions G24 and I26, termed as
IAPP-GI [28]. The presence of two N-methyl rests on the
same side of a β-strand interferes with the interstrand amide
hydrogen-bondingnecessaryforβ-sheetformation[29].The
IAPP-GI analogue was shown to be a nanomolar aﬃnity
inhibitor of hIAPP ﬁbrillization and cytotoxicity. However,
although IAPP-GI did not form amyloid ﬁbrils, it was found
to have a “pronounced self-association propensity” and to
form spheroids of up to 100nm in diameter. Moreover, the
Far-UV circular dichroism (CD) analysis of IAPP-GI indi-
cated the presence of β-sheet and/or β-turn conformations.
These insinuate the presence of another recognition and self-
assembly domain besides the 20–29 region that enabled the
formation of the observed structures. A reminiscent scenario
exists in the study of peptide nanotubes and nanostructures,
which was initiated from the search for a minimal amyloido-
genic core domain of Alzheimer’s β-amyloid polypeptide.
While the Phe-Phe dipeptide was shown to form well-
discrete peptide nanotubes [30], two other peptides, Cys-
Phe-Phe and diphenylglycine, which are very similar to the
diphenylalanine, formed closed-cage nanospheres [31]. We
speculate that the remarkable inhibition ability of the IAPP-
GI analogue is actually due to its high aﬃnity recognition
to the 3–18 site, as it is kept unmodiﬁed and thus provides
maximal compatibility.
The search for inhibitors against amyloid formation led
to the identiﬁcation of insulin as an exceptional inhibitor
of IAPP ﬁbrillization [32–34]. This ﬁnding may be of
high physiological importance as IAPP and insulin are
costored and cosecreted from the pancreatic β-cell granules.
Consequently, insulin is considered to form a complex with
IAPP which stabilizes it and prevents it from aggregation
within the granules [35, 36]. In order to reveal the molecular
mechanism underlying the interaction between IAPP and
insulin, we performed a molecular mapping of the interac-
tion interface. Using a reductionist approach and peptide
arrays, we located the cross-recognition sites within both
polypeptides [37]. Interestingly, insulin was found to bind
to the 13–18 region within IAPP. In addition, the identiﬁed
recognition site within insulin, which resides within the
insulin B chain, was previously shown to have sequence
similarity to the hIAPP(13–18) region [35]. These ﬁndings
reveal a typical amyloid inhibition mechanism for insulin
andreinforcethecentralroleofthe13–18region:thebinding
of insulin to IAPP self-recognition site is mediated through
sequence similarity, it interferes with IAPP self-association
and prevents it from amyloid formation.
3.4. InteractionofIAPPwiththemembrane
As in the case of other amyloid-related disease, the mech-
anism by which IAPP causes cell destruction is assumed to
involve interaction with the cell membrane. Diﬀerent studies
have investigated the possible interaction of IAPP with the
membrane, mostly by the use of membrane mimetics such
as liposomes and phospholipid assemblies. In a recent study,
hIAPP was claimed to insert into phospholipid monolayer
as a monomer [38]. Interestingly, it was suggested that the













Figure 1: Morphology of the formed structures. Electron micro-
scopic examination of negatively stained samples of the studied
peptides: (a) C2, (b) H2, (c) C1, and (d) H1. The C1 peptide failed
to form tubular structures as did the other peptides. (e) and (f) are
high magniﬁcation micrographs of the marked rectangle areas of
C1 and H1, respectively.
Experiments using fragments of hIAPP showed that a pep-
tide consisting of the 19 N-terminal residues of hIAPP
eﬃciently inserts into a phospholipids monolayer, whereas
the 20–29 residue peptide inserts much less eﬃciently. These
results oﬀer a possible role for the N-terminal region also
in the sense of interaction with the pancreatic β-cells which




Cats are among the few mammalian species that are known
to suﬀer from type II diabetes and from accumulation of
IAPP islet amyloid deposits [39, 40]. The cat IAPP (cIAPP)
sequence diﬀers from that of hIAPP in only four amino
acids, at positions 17, 18, 23, and 29. The decapeptide
corresponding to cIAPP(20–29) was previously shown to
be able to aggregate into amyloidal structures as well [16,
41, 42], thus supporting the apparent ﬁbrillization role of
the 20–29 region. However, both the dog and cat IAPP are
identical over the 20–29 region [43] and dogs are not known
to develop type II diabetes.
Table 1: The studied peptides. Peptide fragments corresponding to
regions within the human and cat IAPP were tested for the ability
to form amyloid-like structures.
Name Origin Sequence Residues
C1 cat NLGAILSP 22–29
H1 human NFGAILSS 22–29
C2 cat NFLIRSS 14–20
H2 human NFLVHSS 14–20
In order to re-evaluate the role of the two identiﬁed
recognition sites of IAPP in the ﬁbrillization process, we
tested the self-assembly propensity of peptide fragments
derived from the cat IAPP, cIAPP(22–29), and cIAPP(14–
20). We also tested the aggregation of the correspond-
ing human sequence peptides for reference. The peptide
sequences are presented in Table 1.T h ep e p t i d e sw e r e
dissolved into aqueous solution, under the exact same
conditions, incubated for one to three days and tested for
amyloid formation by electron microscopy (EM) and Congo
Red (CR) birefringence. Their secondary conformation was
also evaluated by Fourier-transform infrared spectroscopy
(FTIR).
Diﬀerencesbetweenthepeptidesappearedalreadybefore
applying the amyloid tests. Upon dilution of the peptides
into aqueous solution, the H1 peptide immediately precipi-
tated into eye-visible aggregates. The other peptide solutions
appeared clear to the unarmed-eye. Examination of the
peptide samples under the electron microscope revealed
the presence of well-ordered tubular structures for all the
peptides except the C1 peptide (Figure 1). Apparently, the
peptides were found to form nanotubes rather than ﬁbrils.
The formation of tubular structures by H2 and H1 was
previously shown [18, 20, 44]. Here we found that the C2
peptidecanalsoformhighlydeﬁnedtubularstructures.Thin
ﬁbrils were also detected in proximity with the nanotubes
or in independent bundles (not shown). The C2 sample
contained mostly nanotubes, the H2 sample contained
nanotubes and ﬁbrils, and the H1 sample contained also
large aggregates. The C1 peptide however did not form
ﬁbrils or tubes, only less ordered spherical structures and
aggregates were observed. The spherical structures may be
reminiscing the ones observed for the IAPP analogue IAPP-
GI [28], which were discussed above, however they are less
ordered than the last ones.
Upon staining with the Congo Red dye, the C2 and H2
samples exhibited clear gold-green birefringence (Figure 2).
In the H1 sample, the dye appears to be bound, however,
no green color was detected. Possibly, the large amount of
aggregates, which were present in addition to the ﬁbrillar
and tubular structures, were shielding over them. No
birefringence or CR binding was shown in the C1 sample,
the slide looked quite clean. Secondary structure analysis
of the peptides by FTIR showed large β-sheet content for
all the peptides (Figure 3). The β-sheet conformation is
characteristic of amyloid-like structures, but is not exclusive
for them. The C1 peptide, negatively detected for amyloid
structures, also displayed β-sheet conformation which mayS. Gilead and E. Gazit 5
(a) (b) (c) (d)
Figure 2: Congo Red binding and birefringence. Microscopic examination under cross-polerizers upon staining with Congo Red of samples


































































Figure 3: Secondary conformation of the formed structures. Fourier-transform infrared (FTIR) spectroscopy analysis of the secondary
conformation of the peptides: (a) C2, (b) H2, (c) C1, and (d) H1. All the peptides exhibited spectra typical for β-sheet secondary structure.
be attributed to the spheroid structures observed by the EM
or to its soluble form.
The comparison between the two cat derived peptides
reveals that the C2 peptide, containing residues 14–20, is
much more competent for self-assembly into amyloid-like
structures than the C1 peptide, composed of residues 22–
29. Although a longer version of the C1 peptide, composed
of residues 20–29, was previously shown to form ﬁbrillar
structures [41, 42], in the present experimental setup it
was unable to form such ﬁbrils. We consider this diversity
to result from the length of the peptide and diﬀerent
experimental conditions, which are in the present assay
of more physiologically-relevant environment and of lower
concentration. Nevertheless, when compared to the C2 pep-
tide,C1isdramaticallylesspotentforﬁbrilformation.While
the C1 peptide may contain self-association properties as
observed by the presence of spherical structures and β-sheet
content, the C2 peptide exhibited self-assembly potency
into well-ordered macromolecular ﬁbrils, which were not
displayed by the C1 peptide. This observation provides fresh
supporting evidence for the central role of the 13–18 region
within the IAPP molecule in amyloid formation: while in
hIAPP both regions are highly amyloidogenic, in the cat
IAPP, there is a clear diﬀerence between the two peptides.
Diﬀerent behavior was also observed for the two human
derived peptides H1 and H2, which may insinuate their
diverse roles in the amyloidogenic process. The H1 peptide
seems to be highly aggregative since visible precipitates were6 Experimental Diabetes Research
observed upon dilution into aqueous solution as well as
under the EM. The H2 peptide however seems to have
higher ability to form well-ordered structures which requires
speciﬁc recognition. Its solution was visibly clear and EM
examination revealed only ﬁbrilar and tubular structures
without aggregates. In addition, green birefringence upon
CR binding, which is characteristic of ordered structures,
was observed in the H2 sample but not in the H1 sample.
Consistent with this observation is the diﬀerent recognition
aﬃnity of the two peptide fragments to the full-length IAPP
as we have previously showed by the peptide array assay [20].
The C1 peptide is not as aggregative as the H1 peptide,
although it contains some structural features as observed
by the FTIR and EM analyses. A comparison between these
two sequences in their longer versions of residues 20–29 was
previously performed by Ashburn and Lansbury [42]. In
this study, both peptides were found to form amyloid ﬁbrils,
however, with remarkably diﬀerent kinetics. The cIAPP(20–
29)peptideformedﬁbrilsapproximately13-foldmoreslowly
than its human version. This correlates with our results
regarding the diﬀerent potency for ﬁbrillization of the two
sequences. It is likely that with a longer incubation period,
the cIAPP(22–29) would also ﬁbrillate eventually.
The cIAPP sequence diﬀers from the hIAPP sequence by
aLeuinsteadofaPheatposition23andaProinsteadofaSer
at position 29. Both modiﬁcations were shown to separately
inﬂuence the kinetics of the peptide ﬁbrillization [42]. It
seems obvious that a Ser to Pro substitution will decrease the
ﬁbrillizationpotency,sinceProisastrongβ-breakerelement.
Regarding the Phe to Leu substitution, we speculate that
the Phe residue facilitates the ﬁbrillization process through
aromatic interactions. According to our established hypoth-
esis, aromatic residues and interactions largely enhance the
processofamyloidformationbyprovidingdirectionalityand
stability to the growing ﬁbril [45–49].
3.6. Intra-β-sheetmechanismfor
IAPPamyloidformation
The accumulated data presented in this paper prove that
none of the two amyloidogenic regions within IAPP can
be ignored. A possible mechanism underlying the self-
assembly of IAPP into amyloid ﬁbrils includes a role for
both regions. It was already suggested in 2001 by Jaikaran
and Clark that the structural transition of IAPP into
amyloid ﬁbrils involves in interactions between β-stranded
regions within the monomer [4]. According to their model,
an intramolecular β-sheet is formed by three β-strands
composed of the segments 8–20, 24–29, and 32–37. Earlier
secondary structure prediction based on IAPP sequence
provided support to their model by predicting β-turns at
positions 20 and 31, as well as β-strands for residues 14–
18 and 26–29 [50]. More recently, another model for the
structure of IAPP within the amyloid ﬁbril was proposed.
Accordingly, the same three β-strands are present, however,
arranged in a zigzag planar s-shaped β-sheet, instead of the
previously proposed e-shaped structure [51].
The presence of an intramolecular β-sheet in the ﬁbrillar
structure of IAPP is supported by the identiﬁcation of
long-range interactions between distinct residues within the
IAPPmolecule.Usingﬂuorescenceresonanceenergytransfer
(FRET), the tyrosine at position 37 was shown to be close
in space to the two phenylalanine residues (F23 and F15)
at the ﬁbrillogenic state of hIAPP [52]. Another interesting
point arises from the genetic background of type II diabetes.
Although the disease is predominantly sporadic, a mutation
in hIAPP sequence, the S20G mutation, which is identiﬁed
among the Japanese population, was found to be related
to early onset of the disease [53]. The S20G mutant was
also shown to exhibit increased ﬁbrillization and cytotoxicity
compared to wild-type hIAPP [54]. Indeed, according to
the intra-β-sheet models, the mutation is placed in a β-turn
region, which is favorable for the glycine residue.
4. CONCLUSIONS
The formation of amyloid deposits by IAPP appears to
play a central role in the pathogenesis of type II diabetes.
Knowledge regarding the exact mechanism of this process
may be highly relevant for the development of therapeutic
agents for the treatment of the disease. Although it is
clear that many environmental factors are involved in this
process, understanding the amyloid formation route at the
molecular level may be highly valued. In this paper, we
have summarized results from several research groups which
support the notion that the 20–29 region within IAPP
cannot be considered as the sole amyloidogenic core of the
polypeptide. By reviewing previously published data, by us
and others, as well as providing experimental data regarding
the amyloidogenicity of the 13–18 region derived from the
cat IAPP, we emphasized the essential role of the 13–18
region in the ﬁbrillization process of IAPP. We conclude that
an intramolecular β-sheet structure, formed by at least the
two discussed regions, may provide a very good mechanism
to the discussed observations.
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